TIAMUTIN PREMIX 2% W/W PREMIX FOR MEDICATED FEED FOR PIGS, CHICKENS AND RABBITS

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Buy It Now

Active ingredient:

TIAMULIN FUMARATE

Available from:

Elanco Europe Ltd

ATC code:

QJ01XQ01

INN (International Name):

TIAMULIN FUMARATE

Dosage:

2 %w/w

Pharmaceutical form:

Premix for Med.Feedstuffs

Prescription type:

POM

Therapeutic group:

Fowl - Chicken, Fowl - Turkey, Porcine, Rabbits

Therapeutic area:

Tiamulin

Therapeutic indications:

Antibacterial

Authorization status:

Authorised

Authorization date:

2016-10-21

Summary of Product characteristics

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Tiamutin Premix 2% w/w
Premix for medicated feed for pigs, chickens and rabbits.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Tiamulin hydrogen fumarate
20 mg/g
_Excipients: _For full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Premix for medicated feeding stuff.
Brown, free-flowing granulate.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Pigs.
Chickens (broiler, replacement pullet, layer/breeder).
Turkeys (poult (grower) and breeder).
Rabbits.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Pigs
For the treatment and prevention of swine dysentery caused by _Brachyspira hyodysenteriae_.
For the treatment of colitis caused by _Brachyspira pilosicoli_.
For the treatment of ileitis caused by _Lawsonia intracell_ularis.
For the treatment of enzootic pneumonia caused by _Mycoplasma hyopneumoniae_.
Chickens
For the treatment and prevention of chronic respiratory disease (CRD) and air sacculitis caused by _Mycoplasma_
_gallisepticum _and _Mycoplasma synoviae_.
Turkeys
For the treatment and prevention of infectious sinusitis and air sacculitis caused by _Mycoplasma gallisepticum_,
_Mycoplasma meleagridis _and _Mycoplasma synoviae_.
Rabbits
For the treatment and prevention of epizootic rabbit enterocolitis (ERE).
4.3 CONTRAINDICATIONS
Animals should not receive products containing ionophores (monensin, narasin or salinomycin) during or for at least seven
days before or after treatment with tiamulin. Severe growth depression or death may result.
Refer to section 4.8 for information regarding interaction between tiamulin and ionophores.
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 21/10/2016_
_CRN 7023013_
_p
                                
                                Read the complete document
                                
                            

Search alerts related to this product